# US 2026/0256954 A1 · Combination therapy for treating cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0256954 A1
- Document ID: US20260256954A1
- Status: Published application
- Kind: A1
- Application number: 19/068,709
- Filed: 2025-03-03
- Published: 2026-09-03
- Earliest claimed: 2025-03-03
- Assignees: Ism Biosciences LLC
- Applicants: Ism Biosciences LLC
- Inventors: Max Temnik; Victor Gurin; Sergey Gurin
- Web page: https://patentgrep.com/patent/US20260256954A1

## CPC

- A61K 33/30: Zinc; Compounds thereof
- A61K 51/0406: {Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines}
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4164: 1,3-Diazoles
- A61K 31/655: Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/34: Copper; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61K 2121/00: Preparations for use in therapy
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating cancer or cancer metastasis comprising administering to a patient in need thereof a therapeutically effective amount of one or more anticancer agent selected from the group consisting of chemotherapy, an immunotherapy, a kinase inhibitor, a monoclonal antibody, and an antibody-drug conjugate, and at least one isotope selective modulator inclusive of at least one isotope selected from the group consisting of 63Cu, 64Zn, 66Zn, and 85Rb, wherein said isotope is enriched to exceed 99% atomic mass.

## Claims

### Claim 1

A method of treating a primary melanoma cancer with a combination therapy comprising administering to a patient in need thereof:
(i) a therapeutically effective amount of one or more anticancer agents selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent, a kinase inhibitor, a monoclonal antibody, and an antibody-drug conjugate, and
(ii) a therapeutically effective amount of at least one isotope selective modulator inclusive of at least one isotope selected from the group consisting of 63Cu, 64Zn, 66Zn, and 85Rb, wherein said isotope is enriched to exceed 99% atomic mass;
wherein said anti-cancer agent(s) are known to be effective against primary melanoma cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein said isotope selective modulator is administered prior to, concurrently with, or sequentially to administering said one or more cancer therapies.

### Claim 3 (depends on 1)

The method of claim 1, wherein said isotope selective modulator is administered intravenously.

### Claim 4 (depends on 1)

The method of claim 1, wherein said isotope selective modulator is administered intratumorally.

### Claim 5 (depends on 1)

The method of claim 1, wherein said isotope selective modulator is optionally administered in combination with at least one amino acid enriched to at least 90% L-enantiomer, a flavonoid, a carotenoid, or a polyphenol.

### Claim 6

A method of treating a metastatic melanoma cancer with a combination therapy comprising administering to a patient in need thereof:
(i) a therapeutically effective amount of one or more anti-cancer agents selected from the group consisting of a chemotherapeutic agent, an immunotherapeutic agent, a kinase inhibitor, a monoclonal antibody, and an antibody-drug conjugate, and
(ii) a therapeutically effective amount of at least one isotope selective modulator inclusive of at least one isotope selected from the group consisting of 63Cu, 64Zn, 66Zn, and 85Rb, wherein said isotope is enriched to exceed 99% atomic mass;
wherein said anti-cancer agent(s) are known to be effective against said metastatic melanoma cancer.

### Claim 7 (depends on 6)

The method of claim 6, wherein said isotope selective modulator is administered prior to, concurrently with, or sequential to administering said one or more cancer therapies.

### Claim 8 (depends on 6)

The method of claim 6, wherein said isotope selective modulator is administered intravenously.

### Claim 9 (depends on 6)

The method of claim 6, wherein said isotope selective modulator is administered intratumorally.

### Claim 10 (depends on 6)

The method of claim 6, wherein said isotope selective modulator is optionally administered in combination with at least one amino acid enriched to at least 90% L-enantiomer, a flavonoid, a carotenoid, or a polyphenol.
